Formulation Development
Encoded Therapeutics Partners With Genedata to Accelerate AAV-Based Gene Therapy Development
Genedata recently announced that Encoded Therapeutics has chosen Genedata Bioprocess to digitalize their proprietary gene therapy R&D technology…..
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative & Biothreat Pathogens
Entasis Therapeutics Holdings Inc. recently announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and…
Atea’s Oral Antiviral Drug Candidate Reduces Viral Replication in Hospitalized Patients With COVID-19 in Phase 2 Interim Analysis
Atea Pharmaceuticals, Inc. recently announced positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche and Atea…
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients With Chronic Rhinosinusitis
Lyra Therapeutics, Inc. recently announced positive topline results from the company’s pharmacokinetic (PK) study of LYR-210. Data obtained from the study are supportive of LYR-210’s…
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles
Halberd Corporation recently announced a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated…
OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi
OSE Immunotherapeutics and Cenexi recently announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate against COVID-19 currently…
Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial
Altimmune, Inc. recently provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The company also provided an update on its T-COVID…
Evonik Markets Novel Chemical Technology for More Sustainable Pharmaceutical Production
Evonik offers an innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water. The “Chemistry in Water” technology has the potential….
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
LEXEO Therapeutics recently announced the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of….
InMed Pharmaceuticals Signs Non-Binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
InMed Pharmaceuticals Inc. recently announced it has entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of….
eTheRNA immunotherapies & Quantoom Biosciences Announce Strategic Collaboration for the Development of a Novel RNA Production
eTheRNA immunotherapies NV and Quantoom Biosciences S.A. recently announced they are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material…..
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Adocia recently announced the launch of a Phase 1 clinical study in collaboration with Dr. Ahmad Haidar, McGill University, Canada, to assess pharmacokinetic, glycemic control…
CN Bio’s PhysioMimix Adopted by King’s College London to Investigate Chronic Liver Disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), recently announced that King’s College London, an internationally…
Orchard Therapeutics Announces Regulatory & Clinical Updates for Lead Gene Therapy Programs
Orchard Therapeutics recently announced several program updates for the company’s portfolio of approved and investigational hematopoietic stem cell (HSC) gene therapies. These updates follow recent…
CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed & Recurrent Urothelial Cancer Patients
CicloMed LLC recently announced that the Phase 1B clinical trial of fosciclopirox for the treatment of bladder cancer is now open. “We are excited to…
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study With Dipraglurant for Dyskinesia Associated With Parkinson’s Disease
Addex Therapeutics Ltd recently announced that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease…
2021 Respiratory Drug Development eBook – The Three Cs Driving Respiratory Drug Delivery
In this third annual Drug Development & Delivery Respiratory eBook, several companies discuss what they are currently working on to propel the respiratory sector.
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study
Crinetics Pharmaceuticals, Inc. recently announced the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing….
Roquette Boosts Customer Support With New Digital Pharma Marketplace
Roquette recently announced the opening of its new pharma online marketplace, powered by Knowde. The e-commerce platform will provide users….
Agios Submits MAA to EMA for Mitapivat for Treatment of Adults With Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc. recently announced it has submitted a Marketing Authorization Application (MAA) for mitapivat to the European Medicines Agency (EMA) for the treatment of adults with pyruvate kinase….